DAHANCA: Difference between revisions
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
'''DAHANCA''' refers to the "Danish Head and Neck Cancer Study". It actually refers to a series of studies, the most recent of which is "DAHANCA 10". Other notable studies include DAHANCA 5<ref>{{cite journal |author=Eriksen JG, Overgaard J |title=Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study> |journal= |volume= |issue= |pages= |year=2007 |pmid=17543403 |doi=10.1016/j.radonc.2007.05.009}}</ref> and DAHANCA 6/7.<ref>{{cite journal |author=Overgaard J, Hansen HS, Specht L, ''et al'' |title=Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial |journal=Lancet |volume=362 |issue=9388 |pages=933-40 |year=2003 |pmid=14511925 |doi=}}</ref> | '''DAHANCA''' refers to the "Danish Head and Neck Cancer Study". It actually refers to a series of studies, the most recent of which is "DAHANCA 10". Other notable studies include DAHANCA 5<ref>{{cite journal |author=Eriksen JG, Overgaard J |title=Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study> |journal= |volume= |issue= |pages= |year=2007 |pmid=17543403 |doi=10.1016/j.radonc.2007.05.009}}</ref> and DAHANCA 6/7.<ref>{{cite journal |author=Overgaard J, Hansen HS, Specht L, ''et al'' |title=Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial |journal=Lancet |volume=362 |issue=9388 |pages=933-40 |year=2003 |pmid=14511925 |doi=}}</ref> | ||
| Line 15: | Line 15: | ||
* http://www.dahanca.dk/ | * http://www.dahanca.dk/ | ||
[[Category: Medical terms]] | [[Category: Medical terms]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 00:26, 9 August 2012
|
WikiDoc Resources for DAHANCA |
|
Articles |
|---|
|
Most recent articles on DAHANCA |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on DAHANCA at Clinical Trials.gov Clinical Trials on DAHANCA at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on DAHANCA
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating DAHANCA Risk calculators and risk factors for DAHANCA
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for DAHANCA |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
DAHANCA refers to the "Danish Head and Neck Cancer Study". It actually refers to a series of studies, the most recent of which is "DAHANCA 10". Other notable studies include DAHANCA 5[1] and DAHANCA 6/7.[2]
It operates under the authority of the Danish Society for Head and Neck Oncology.
See also
References
- ↑ Eriksen JG, Overgaard J (2007). "Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study>". doi:10.1016/j.radonc.2007.05.009. PMID 17543403.
- ↑ Overgaard J, Hansen HS, Specht L; et al. (2003). "Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial". Lancet. 362 (9388): 933–40. PMID 14511925.